Compare Cytokinetics Inc (CYTK) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Ecopetrol SA — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Ecopetrol SA trades at $16.93 (market cap $34.09B). The key difference: Ecopetrol SA is far larger — about 4× Cytokinetics Inc's market cap, and Ecopetrol SA pays a 3.91% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Ecopetrol SA for 84 Days on average.
| CYTK | EC | |
|---|---|---|
Market Cap | $8.50B | $34.09B |
Volume | 2,395,556 | 952,204 |
Sector | Health | Energy |
52-Week High | $87.26 | $18.26 |
52-Week Low | $54.76 | $8.61 |
Typical Hold Time | 19 Days | 84 Days |
Enterprise Value | $8.60B | $62.65B |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Ecopetrol (EC) trades at $16.94, down 0.12% with bearish technical signals. The stock shows attractive valuation metrics including P/E of 7.99 and P/S of 0.91, but faces declining revenue from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while the company maintains positive cash flow from operations despite recent earnings misses.
EC presents a value opportunity with discounted multiples but faces operational headwinds. The key investment thesis balances cheap valuation against declining revenue trends and political uncertainty. Risks include continued earnings volatility and government influence, while potential upside exists if new management can stabilize operations and reverse the revenue decline trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
